Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. Companies specializing in drug ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company delivered weak fourth-quarter 2024 results, with sales, ...

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has received a consensus rating of “Reduce” from the twelve analysts ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings ... we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI.

Jill G. McConnell, the Chief Financial Officer of Fortrea Holdings Inc. (NASDAQ:FTRE), recently sold shares of the company’s... ByInvesting.com • 1 hour ago FTRE stock touches 52-week low at $ ...

FORTREA ($FTRE) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of $0.18 per share, missing estimates of $0.37 by $0.19. The ...

(FTRE) came out with quarterly earnings of $0. ... The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly ...